Xeris Pharmaceuticals Inc (XERS)

Trade XERS now with
3/11/2020 6:05:35 AM Xeris Pharma Q4 Net Loss Of $33.1 Mln Or $1.23/Shr Vs Loss Of $20.4 Mln Or $0.98/Shr Last Year
2/11/2020 7:31:41 PM Xeris Pharma Prices Underwritten Public Offering Of 9 Mln Shares At $4.15/shr
10/4/2019 6:15:36 AM New Drugs Approved In September
9/19/2019 8:09:16 AM Xeris Pharma Begins Dosing Patients In Phase 2 Clinical Trial Of Novel Fixed-Ratio Co-Formulation Of Pramlintide-Insulin
6/27/2019 8:05:05 AM Xeris Doses First Subject In Phase 2 Trial With Ready-to-use Glucagon
6/6/2019 4:12:36 PM Xeris Pharmaceuticals Trading Expected To Resume At 4:30 PM ET
6/6/2019 4:03:41 PM Xeris Pharmaceuticals Trading Halted; Pending News
2/13/2019 7:54:24 PM Xeris Prices Public Offering Of 5.88 Mln Shares At $10.00/shr
12/20/2018 8:33:25 AM EMA Grants Orphan Drug Designation For Xeris’ Investigational Ready-to-Use Glucagon For Treatment Of NIPHS
11/7/2018 8:15:09 AM Xeris Pharmaceuticals Q3 Net Loss Widens To $14.8 Mln From $7.5 Mln Last Year
10/23/2018 8:35:57 AM Xeris Pharma Announces FDA Acceptance For Review Of NDA For Ready-to-Use Glucagon Rescue Pen
8/17/2018 8:31:16 AM Xeris Pharma And OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon